May 29, 2019 7:00am EDT Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update
May 23, 2019 7:00am EDT The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
May 20, 2019 7:00am EDT Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
May 06, 2019 7:00am EDT Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
Apr 15, 2019 7:00am EDT Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
Apr 10, 2019 7:07am EDT Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
